Teclistamab Improves Patient-Reported Symptoms and Health-Related Quality of Life in Relapsed or Refractory Multiple Myeloma: Results From the Phase II MajesTEC-1 Study

Patients with relapsed or refractory multiple myeloma (RRMM) report significantly lower HRQoL compared with patients with newly diagnosed MM and experience further deterioration in HRQoL with each relapse and subsequent treatment. Therefore, consideration of the impact of treatment on HRQoL in addit...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Clinical lymphoma, myeloma and leukemia myeloma and leukemia, 2024-03, Vol.24 (3), p.194-202
Hauptverfasser:	Martin, Thomas G., Moreau, Philippe, Usmani, Saad Z., Garfall, Alfred, Mateos, María-Victoria, San-Miguel, Jesús F., Oriol, Albert, Nooka, Ajay K., Rosinol, Laura, Chari, Ajai, Karlin, Lionel, Krishnan, Amrita, Bahlis, Nizar, Popat, Rakesh, Besemer, Britta, Martínez-López, Joaquín, Delforge, Michel, Trancucci, Danielle, Pei, Lixia, Kobos, Rachel, Fastenau, John, Gries, Katharine S., van de Donk, Niels W.C.J.
Format:	Artikel
Sprache:	eng
Schlagworte:	Antineoplastic Agents - therapeutic use B-cell maturation antigen Bispecific antibody EORTC QLQ-C30 EQ-5D-5L Humans Life Sciences Multiple Myeloma - drug therapy Neoplasm Recurrence, Local - drug therapy Pain - drug therapy Patient Reported Outcome Measures Patient-reported outcomes Quality of Life
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!